CL2022003511A1 - Inhibidores de alk2 para el tratamiento de la anemia. - Google Patents

Inhibidores de alk2 para el tratamiento de la anemia.

Info

Publication number
CL2022003511A1
CL2022003511A1 CL2022003511A CL2022003511A CL2022003511A1 CL 2022003511 A1 CL2022003511 A1 CL 2022003511A1 CL 2022003511 A CL2022003511 A CL 2022003511A CL 2022003511 A CL2022003511 A CL 2022003511A CL 2022003511 A1 CL2022003511 A1 CL 2022003511A1
Authority
CL
Chile
Prior art keywords
anemia
treatment
alk2 inhibitors
alk2
inhibitors
Prior art date
Application number
CL2022003511A
Other languages
English (en)
Inventor
Yaoyu Chen
Francis Séguy
Ekaterine Asatiani
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of CL2022003511A1 publication Critical patent/CL2022003511A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En el presente documento se proporcionan métodos para tratar la anemia en un sujeto que lo necesita, que comprenden administrar al sujeto una cantidad terapéuticamente eficaz de un inhibidor de ALK2.
CL2022003511A 2020-06-16 2022-12-09 Inhibidores de alk2 para el tratamiento de la anemia. CL2022003511A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063039742P 2020-06-16 2020-06-16
US202063056761P 2020-07-27 2020-07-27
US202163152516P 2021-02-23 2021-02-23

Publications (1)

Publication Number Publication Date
CL2022003511A1 true CL2022003511A1 (es) 2023-06-02

Family

ID=76845323

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2022003511A CL2022003511A1 (es) 2020-06-16 2022-12-09 Inhibidores de alk2 para el tratamiento de la anemia.
CL2023001952A CL2023001952A1 (es) 2020-06-16 2023-06-30 Inhibidores de alk2 para el tratamiento de la anemia (divisional).

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2023001952A CL2023001952A1 (es) 2020-06-16 2023-06-30 Inhibidores de alk2 para el tratamiento de la anemia (divisional).

Country Status (12)

Country Link
US (2) US11723899B2 (es)
EP (1) EP4164641A1 (es)
JP (1) JP2023530316A (es)
KR (1) KR20230025444A (es)
CN (1) CN115968289A (es)
AU (1) AU2021292484A1 (es)
CA (1) CA3187767A1 (es)
CL (2) CL2022003511A1 (es)
IL (1) IL298767A (es)
MX (1) MX2022015900A (es)
TW (1) TW202214239A (es)
WO (1) WO2021257532A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023502742A (ja) 2019-11-22 2023-01-25 インサイト コーポレーション Ａｌｋ２阻害剤及びｊａｋ２阻害剤を含む併用療法
IL298767A (en) 2020-06-16 2023-02-01 Incyte Corp ALK2 inhibitors for the treatment of anemia
WO2022240948A1 (en) * 2021-05-11 2022-11-17 Keros Therapeutics, Inc. Methods of using alk2 and alk3 antibodies
WO2023198114A1 (zh) * 2022-04-13 2023-10-19 杭州邦顺制药有限公司 Alk2激酶抑制剂

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077290A (en) 1990-10-11 1991-12-31 Merck & Co., Inc. Morpholine derivatives compositions and use
TW530054B (en) 1997-09-24 2003-05-01 Duphar Int Res New piperazine and piperidine compounds
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
CA2484209C (en) 2002-05-03 2013-06-11 Exelixis, Inc. Protein kinase modulators and methods of use
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
US20040067985A1 (en) 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
SE0203753D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
AU2004230519A1 (en) 2003-04-11 2004-10-28 Sgx Pharmaceuticals, Inc. Compound libraries and methods for drug discovery
CA2567935C (en) 2004-05-27 2009-10-27 Pfizer Limited Aminopyridine derivatives as selective dopamine d3 agonists
SA05260265A (ar) 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
EP1875912A4 (en) 2005-04-08 2008-06-04 Eisai R&D Man Co Ltd MEANS OF TREATING UNWILLING MOVEMENTS
WO2007011760A2 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
AR059036A1 (es) 2006-01-17 2008-03-12 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
WO2008002671A2 (en) 2006-06-29 2008-01-03 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors
AU2009271414A1 (en) 2008-06-20 2010-01-21 Metabolex, Inc. Aryl GPR119 agonists and uses thereof
WO2012088438A1 (en) 2010-12-22 2012-06-28 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
LT2714677T (lt) 2011-05-23 2018-12-10 Merck Patent Gmbh Piridino ir pirazino dariniai
SG2014013767A (en) 2011-09-09 2014-05-29 Lantheus Medical Imaging Inc Compositions, methods, and systems for the synthesis and use of imaging agents
US9738636B2 (en) 2012-09-28 2017-08-22 Vanderbilt University Fused heterocyclic compounds as selective BMP inhibitors
US20160115167A1 (en) 2013-03-04 2016-04-28 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
WO2014151871A2 (en) 2013-03-14 2014-09-25 Tolero Pharmaceuticals, Inc. Jak2 and alk2 inhibitors and methods for their use
RS59140B1 (sr) 2013-10-21 2019-09-30 Merck Patent Gmbh Heteroarilna jedinjenja kao inhibitori btk i njihova upotreba
MX2017009408A (es) 2015-01-20 2017-10-02 Merial Inc Compuestos antihelminticos, composiciones y metodo para usar los mismos.
BR112018004065B1 (pt) 2015-08-31 2023-12-12 Dong-A Socio Holdings Co., Ltd Compostos heterocíclicos, composições farmacêuticas compreendendo os ditos compostos e usos terapêuticos dos mesmos
WO2018014829A1 (en) 2016-07-20 2018-01-25 Novartis Ag Aminopyridine derivatives and their use as selective alk-2 inhibitors
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
US20220372136A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating anemia of chronic disease
WO2021062163A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
JP2023502742A (ja) 2019-11-22 2023-01-25 インサイト コーポレーション Ａｌｋ２阻害剤及びｊａｋ２阻害剤を含む併用療法
IL298767A (en) 2020-06-16 2023-02-01 Incyte Corp ALK2 inhibitors for the treatment of anemia

Also Published As

Publication number Publication date
TW202214239A (zh) 2022-04-16
US20230338352A1 (en) 2023-10-26
WO2021257532A1 (en) 2021-12-23
CL2023001952A1 (es) 2023-12-15
US11723899B2 (en) 2023-08-15
CA3187767A1 (en) 2021-12-23
MX2022015900A (es) 2023-01-24
US20210393605A1 (en) 2021-12-23
AU2021292484A1 (en) 2023-01-19
IL298767A (en) 2023-02-01
EP4164641A1 (en) 2023-04-19
KR20230025444A (ko) 2023-02-21
JP2023530316A (ja) 2023-07-14
CN115968289A (zh) 2023-04-14

Similar Documents

Publication Publication Date Title
CL2022003511A1 (es) Inhibidores de alk2 para el tratamiento de la anemia.
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
EA202190630A1 (ru) Способы комбинированной терапии
BR112018073920A2 (pt) inibidores de pd-1/pd-l1 para tratamento de câncer".
EA201992220A1 (ru) Комбинированная терапия для лечения или предупреждения опухолей
EA201690980A1 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
CR20190162A (es) Métodos para usar un anticuerpo biespecífico que reconoce el factor de coagulación ix y/o el factor de coagulación ix activado y el factor de coagulación x y/o el factor de coagulación x activado
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
BR112017018234A2 (pt) inibidores de pd-1 / pd-l1 para o tratamento de câncer
CO2020013600A2 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
EA201892510A2 (ru) Комбинированная терапия для лечения рака
CR20160308A (es) Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
ECSP099376A (es) Inhibidores de la actividad de la akt
BR112021017350A2 (pt) Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
UY33221A (es) MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
BR112021020409A2 (pt) Terapia de combinação com anticorpo anti-bcma e inibidor de gama-secretase
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
CL2021002966A1 (es) Combinación de inhibidores de pd-1 e inhibidores de lag-3 para mejorar la eficacia en el tratamiento del cancer.
BR112023000687A2 (pt) Métodos e combinações de inibidores de kat6 para o tratamento de câncer
CL2020002544A1 (es) Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret
EA202190776A1 (ru) Комбинация маломолекулярных ингибиторов cd-47 с другими противораковыми агентами
ECSP11011405A (es) Terapia de combinación que usa un agente o agentes anti-egfr e inhibidores específicos de igf-1r
AR087902A1 (es) COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
ECSP22044525A (es) Terapia de combinaci?n que comprende un inhibidor de alk2 y un inhibidor de jak2
CL2022000214A1 (es) Inhibidores de enzimas